CATX · Perspective Therapeutics, Inc.
$2.50
-0.27 (-9.60%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$299.08M
Shares
114.15M
Volume · Oct 5
2.96M
Avg daily vol (3M)
1.64M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.76
Open$2.77
Day$2.69–2.82
52W close$2.05–5.65
Avg vol 30d1.9M
Short int22.8M · 20.0% float · 16.9d
Short vol80%
Last earningsJan 13, 2025
DataJan 2020–Oct 2026
Filing10-Q · Aug 10
Up next
filed Aug 10, 2026
call held Nov 10, 2022
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-20.9%
Trailing year
Short interest
20.0%
Latest settlement · 16.9 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−24%
below
Price vs 50-day avg
−7%
below
RSI (14)
47
neutral
MACD trend
Positive
52-week position
20%
mid-range
Momentum
relative strength
1-month return
−12%
trailing
6-month return
−37%
trailing
YTD return
0%
this year
Relative strength
−49%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Distributing
-6% holders QoQ · +23 funds added
Insider flow
Distributing
Net -$1.6M over 90 days · 100% sells
Short interest
Falling
19.98% of float · ▼ -2.3% MoM · 16.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
131 holders — mid 3-yr range
Squeeze score
67
elevated · 0–100
Fundamentals
Revenue growth
+24%
Y/Y
Gross margin
24%
expanding
EPS growth
−14%
Y/Y
Free cash flow
$-95.2M
Balance sheet
$29.0M
net cash
Quant / Vol
risk profile
Volatility
109%
annualized · 1-yr
Max drawdown
−59%
past year
ATR
6.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Sep 17, 2020
Proprietary R&D expense
· going forward
$300,000 – $400,000
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−24%
Bearish
Price vs 50-day avg
−7%
Bearish
RSI (14)
47
Neutral
MACD trend
Positive
Bullish
52-week position
20%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Distributing
-6% holders QoQ · +23 funds added
Insider flow
Distributing
Net -$1.6M over 90 days · 100% sells
Short interest
Falling
19.98% of float · ▼ -2.3% MoM · 16.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
131 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $3 · 20%
Range high $6
vs 200-day avg -24%
vs 50-day avg -7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CATX
this stock
Perspective Therapeutics, Inc.
|
$299.08M | +0.4% | — | — | 20.0% |
|
ABT
Abbott Laboratories
|
$174.90B | -22.2% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.1% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -55.3% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CATX | +9.5% | -11.5% | -36.6% | +0.4% | +0.4% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +9.7% | -11.1% | -48.7% | -0.6% | -12.5% |